Tolvaptan filed for rare kidney disease in Japan
This article was originally published in Scrip
Otsuka Pharmaceutical has submitted an approval application in Japan for its first-in-class oral vasopressin V2 receptor antagonist tolvaptan for the additional orphan indication of autosomal dominant polycystic kidney disease (ADPKD).
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.